Immunology for Engineers
- 1st Edition, Volume 140 - May 16, 2024
- Latest edition
- Editor: Vijay Kumar Prajapati
- Language: English
Immunology for Engineers, Volume 140 consists of chapters from stalwarts of the field, covering topics such as antibody engineering, adjuvant requirement and its methodology for as… Read more
Data Mining & ML
Unlock the cutting edge
Up to 20% on trusted resources. Build expertise with data mining, ML methods.
Description
Description
Key features
Key features
- Presents the latest in immunological engineering
- Delves into timely topics such as antibody engineering
- Covers vaccine engineering amongst many other important topics
Readership
Readership
Table of contents
Table of contents
Vijay Kumar Prapajati
2. Current Status and Future Prospective of Breast Cancer Immunotherapy
Anurag S. Rathore
3. Engineering high affinity antigen binders- beyond antibodies
Rajeev Kumar Pandey
4. Platelets and Inter-Cellular Communication in Immune Responses: Dialogue with both Professional and Non-Professional Immune Cells
Sunil Kumar SINGH
5. Chimeric Antigen Receptor (CAR) T cell-based cancer immunotherapy: A boon for cancer-free life
Bajarang Vasant Kumbhar
6. Molecular insights and promise of Oncolytic Virus based Immunotherapy
Balachandar Vellingiri
Product details
Product details
- Edition: 1
- Latest edition
- Volume: 140
- Published: May 17, 2024
- Language: English
About the editor
About the editor
VP
Vijay Kumar Prajapati
Dr. Vijay Kumar Prajapati is an Associate Professor in the Department of Biochemistry at the University of Delhi South Campus, New Delhi, India. He specializes in cell-death research, parasitology, and therapeutic developments for infectious diseases. He has published extensively in international journals and contributed chapters to reputable publishers. He is a recipient of the INSA Medal for Young Scientist from the Indian National Science Academy and an Associate of the Indian Academy of Sciences, Bengaluru. His work has appeared in leading journals spanning infectious diseases and cellular physiology, reflecting a high scholarly impact and a broad research portfolio.